Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06616597 · ClinicalTrials.gov registry record · Phase 2
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
A Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT06616597 is a Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 58 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06616597, a Phase 2 study of Metastatic Prostate Cancer and Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Metronidazole
- DRUG Abiraterone acetate
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2032-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06616597
The ClinicalTrials.gov registry entry for NCT06616597 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT06616597 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06616597 about?
NCT06616597 is a clinical study titled "Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer". To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
What is the current status of trial NCT06616597?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2025-02-13. Estimated completion is 2032-03-30.
What conditions does trial NCT06616597 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma).
What interventions are being tested in trial NCT06616597?
The interventions under investigation include: Dexamethasone (DRUG), Metronidazole (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT06616597?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06616597 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RECRUITING · Phase 2
-
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.